Biogen Ma, Inc. v. Japanese Foundation for Cancer Research

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• holding that there was appellate jurisdiction over the administrative proceeding at issue pursuant to 35 U.S.C. § 141 , despite the appellant's initial election of district court review under id . § 146 because the district court lacked jurisdiction
• holding that this court has exclusive appellate jurisdiction over Board decisions
• observing that the America Invents Act “changed the patent system, among other things, from a first-to-invent to a first- inventor-to-file regime for determining patent priority”
• explaining that the impact of the TCA was to eliminate district court review of PTAB decisions pursuant to 35 U.S.C. § 146 (allowing de novo review)
• explaining that under AIA § 3(n)(1), “new AIA provisions [apply] only to new applications” and “in- terference proceedings are to continue with respect to . . . applications filed before March 16, 2013.”
• explaining that under AIA § 3(n)(1), “new AIA provisions [apply] only to new applications” and “in- terference proceedings are to continue with respect to . . . applications filed before March 16, 2013.”

Source: CourtListener parenthetical corpus (CC0).